Methods and compositions for wound healing
The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface.
1. A process for manufacture of an article comprising:
a) providing a flexible substrate having a surface area of greater than 0.1 square meters and having a release coated surface selected from the group consisting of a silicone coating, a polydimethyl siloxane (PDMS) coating, a fluorocarbon coating, a polyacrylate coating, a polystyrene coating, a polystyreneacrylic coating, a chromium sterate complex coating, or a polyolefin coating;
b) continuously depositing a nanoscale polymer multilayer from about 0.5 nm to 10000 nm thick on the release coated surface of the flexible substrate by transferring the flexible substrate from a first roll to at least a second roll and coating the low surface energy surface of the flexible substrate with the alternating layers of at least one positively charged polyelectrolyte and at least one negatively charged polyelectrolyte while the flexible substrate is being transferred between the first roll and the second roll; and
c) peeling the nanoscale polymer layer in association with the second polymer layer from the release coated surface of the substrate to provide a free standing microsheet having a surface area of greater than 0.1 square meters.
2. The process of claim 1 , wherein the at least one positively charged polyelectrolyte is selected from the group consisting of poly(allylamine hydrochloride) (PAH), polyl-lysine (PLL), poly(ethylene imine) (PEI), poly(histidine), poly(N,N-dimethyl aminoacrylate), poly(N,N,N-trimethylaminoacrylate chloride), poly(methyacrylamidopropyltrimethyl ammonium chloride), and chitosan.
3. The process of claim 1 , wherein the at least one negatively charged polyelectrolyte is selected from the group consisting of poly(acrylic acid) (PAA), poly(styrenesulfonate) (PSS), alginate, hyaluronic acid, heparin, heparan sulfate, chondroitin sulfate, dextran sulfate, poly(methacrylic acid), oxidized cellulose, carboxymethyl cellulose, polyaspartic acid, and polyglutamic acid.
4. The process of claim 1 , wherein the polyelectrolytes have a unimodal molecular weight distribution in the range of 1 to 10000 kDa or multimodal molecular weight distribution in the range of 1 to 10000 kDa or is a mixture of multiple polymers of unimodal or multimodal molecular weight distribution in the range of 1 to 10000 kDa.
5. The process of claim 1 , wherein the polyelectrolytes are provided in an aqueous solution at a concentration of from 1 to 10000 mM based on polymer repeat unit.
6. The process of claim 5 , wherein the pH of the aqueous polyelectrolyte solution is adjusted so that the polymer is at least 0.01% charged.
7. The process of claim 5 , wherein the aqueous polyelectrolyte solution further comprises inorganic or organic salts in a concentration of from 1 to 10000 mM.
8. The process of claim 1 , further comprising the step of introducing a bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer layer, wherein the bioactive agent is selected from the group consisting of an antimicrobial agent, an antibiofilm agent, a growth factor, a hemostatic agent, a bioactive peptide, a bioactive polypeptide, an analgesic, a local anesthetic, opioid, opioid agonist, opioid antagonist or mixed agonist/antagonist, an anticoagulant, anti-inflammatory agent, and a drug molecule or a drug compound.
9. The process of claim 8 , wherein the antimicrobial agent is a silver ion, silver salt, or silver nanoparticle.
10. The process of claim 8 , wherein the antibiofilm agent is a gallium ion, gallium ion salt, gallium ion nanoparticle, gallium alloy, or an alloy of gallium and silver.
11. The process of claim 8 , wherein said analgesic is selected from the group consisting of bupivacaine, lidocaine, articaine, prilocaine, and mepivacaine.
12. The process of claim 8 , wherein introducing the bioactive agent into the nanoscale polymer layer to provide a bioactive nanoscale polymer layer comprises introducing silver ions into the nanoscale polymer multilayer and reducing the silver ions in situ to provide silver nanoparticles.
13. The process of claim 12 , wherein nanoscale film is doped with silver ions by immersion in silver nitrate solution of concentration of from 0.1 to 10000 mM for from 1 to 3600 seconds.
14. The process of claim 13 , wherein silver ion in nanoscale film is reduced into silver nanoparticles by immersing nanoscale film in a solution of a reducing agent solution of concentration of from 0.1 to 10000 mM for from 1 to 3600 seconds.
15. The process of claim 8 , further comprising from 2 to 20 repetitions of the step of introducing a bioactive agent into the nanoscale polymer layer.
16. The process of claim 8 , wherein the bioactive agent is loaded at a concentration of approximately 0.01 to 1000 μg/cm 2 in the nanoscale polymer layer.
17. The process of claim 1 wherein the second polymer layer slows the release rate of bioactive agent from nanoscale layer by 1 to 1000 times.
18. The process of claim 1 , wherein the second polymer layer comprises polyvinyl alcohol (PVA), polyacrylic acid (PAA), polyvinylpyrrolidone (PVP), carboxymethyl cellulose (CMC), hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, hydroxyethyl cellulose (HEC), alginates, polyvinylacetate (PVAc), polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), polyglycolic acid, or polyanhydrides.
19. The process of claim 1 , wherein the polymer in the second polymer layer has a molecular weight of less than 23 kDa.
20. The process of claim 1 , wherein the second polymer layer is ionically, physically or chemically crosslinked.
21. The process of claim 1 , wherein the second polymer layer is from about 0.1 μm thick to about 100 μm thick.
22. The process of claim 1 , further comprising introducing a bioactive agent into the second polymer layer.
23. The process of claim 22 , wherein the bioactive agent is selected from the group consisting of an antimicrobial agent, an antibiofilm agent, a growth factor, a hemostatic agent, a bioactive peptide, a bioactive polypeptide, an analgesic, an anticoagulant, an anti-inflammatory agent, and a drug molecule or a drug compound.
24. The process of claim 23 , wherein the antimicrobial agent is a silver ion, silver salt, or silver nanoparticle.
25. The process of claim 23 , wherein the antibiofilm agent is a gallium ion, gallium ion salt, gallium ion nanoparticle, gallium alloy, or an alloy of gallium and silver.
26. The article of claim 23 , wherein said local anaesthetic is selected from the group consisting of bupivacaine, lidocaine, articaine, prilocaine, and mepivacaine.
27. The process of claim 22 , wherein the bioactive agent is provided in the second polymer layer at a concentration of approximately 0.01 μg/cm 2 to 10 mg/cm 2 .
28. The process of claim 22 , further comprising including a second or more bioactive agent(s) in the combined nanoscale polymer layer and the second polymer layer.
29. The process of claim 1 , wherein the flexible substrate comprises a polymer film selected from the group consisting of a polyester film, a polyethylene terephthalate (PET) film, a biaxially oriented PET film, a polycarbonate, a polyethylene (including high density polyethylene, medium density polyethylene, low density polyethylene, linear low density polyethylene) film, a polyvinyl chloride film, a polyvinylidene chloride film, a polyvinylidene fluoride film, a nylon film, a polystyrene film, an acetate film, a polyurethane film, an ethylene vinyl acetate copolymer film, a cast polypropylene film, an uniaxially oriented polypropylene film and a biaxially oriented polypropylene film.
30. The process of claim 1 , wherein said second polymer layer comprises one or more additives selected from the group consisting of surfactants, emulsifiers, wetting agents, rheology modifiers, plasticizers, emollients, humectants, disintegrants, lubricants, binders, compatibilizing agents, antistatic agents, and fillers.